Smoking at Diagnosis Is an Independent Prognostic Factor for Cancer-Specific Survival in Head and Neck Cancer: Findings from a Large, Population-Based Study
Authors:
Open Access
- 1 November 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 23 (11) , 2579-2590
Abstract
Background: Some studies suggest smoking may result in poorer clinical outcomes in head and neck cancer, but the evidence is heterogeneous and some of it is poor quality. In a large, population-based, study we investigated: (i) whether smoking at diagnosis is an independent prognostic factor for cancer-specific survival in head and neck cancer; and (ii) whether the association varies by site and treatment. Methods: Head and neck cancers (ICD10 C01-C14, and C30–32) diagnosed from 1994 to 2009 were abstracted from the National Cancer Registry Ireland, and classified by smoking status at diagnosis. Follow-up was for 5 years or until December 31, 2010. Multivariate Cox proportional hazards models were used to compare cancer-specific death rates in current, ex-, and never smokers. Subgroup analyses by site and treatment were conducted. Results: In total, 5,652 head and neck cancers were included. At diagnosis, 24% were never smokers, 20% ex-smokers, and 56% current smokers. Compared with never smokers, current smokers had a significantly raised death rate from cancer [multivariate HR, 1.36; 95% confidence interval (CI), 1.21–1.53]. The association was similar after restriction to squamous cell tumors. A significantly increased cancer-related death rate was seen for current smokers with oral cavity, pharyngeal, and laryngeal cancers. The association was stronger in surgically treated patients [HR, 1.49; 95% CI, 1.25–1.79; P(interaction) = 0.01]. Neither radiotherapy nor chemotherapy modified the effect of smoking. Conclusions: Patients with head and neck cancer who smoke at diagnosis have a significantly increased cancer death rate. Impact: Greater efforts are needed to encourage and support smoking cessation in those at risk of, and diagnosed with, head and neck cancer. Cancer Epidemiol Biomarkers Prev; 23(11); 2579–90. ©2014 AACR.Keywords
All Related Versions
This publication has 74 references indexed in Scilit:
- 2. Tobacco-attributable cancer burden in the UK in 2010British Journal of Cancer, 2011
- XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research, 2011
- Multiple imputation by chained equations: what is it and how does it work?International Journal of Methods in Psychiatric Research, 2011
- Improved Estimates of Cancer-Specific Survival Rates From Population-Based DataJNCI: Journal of the National Cancer Institute, 2010
- Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor RecurrenceClinical Cancer Research, 2010
- Current and potential inflammation targeted therapies in head and neck cancerCurrent Opinion in Pharmacology, 2009
- Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2009
- Inequity in colorectal cancer treatment and outcomes: a population-based studyBritish Journal of Cancer, 2008
- ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiationBritish Journal of Cancer, 2008
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994